The Metabolic Syndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease
Section snippets
C-Reactive Protein and the Metabolic Syndrome in Predicting Coronary Artery Disease and Diabetes
The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) clinical criteria for the metabolic syndrome are shown in Table 1.3 The diagnosis of metabolic syndrome is based on the presence of any 3 of the criteria listed. Several problems have been noted with this definition of the syndrome. First, it can be met without the presence of insulin resistance, which is a central component of the World Health Organization (WHO) definition of the syndrome.4 Second, waist
C-Reactive Protein Levels and Risk of the Metabolic Syndrome
There are data indicating that elevated hs-CRP levels predict development of the metabolic syndrome, at least in women. In 729 women during 6 years of follow-up in the Mexico City Diabetes Study, baseline hs-CRP was significantly correlated with development of the metabolic syndrome, which was defined as including ≥3 of the following: dyslipidemia (elevated triglycerides or low HDL cholesterol), hypertension, or diabetes. In 515 men studied, however, there was no significant correlation.7
C-Reactive Protein, Diabetes, and the Metabolic Syndrome
The Insulin Resistance Atherosclerosis Study (IRAS) found a linear increase in mean log hs-CRP values according to the number of metabolic disorders present in each of 1,008 patients without diabetes or CAD.8 The metabolic disorders consisted of dyslipidemia (elevated triglycerides and/or low HDL cholesterol), upper body adiposity, insulin resistance (measured by frequently sampled intravenous glucose tolerance tests), and hypertension. A prospective study in 1,047 subjects without diabetes in
Effects of Therapy on C-Reactive Protein Levels
Although it is still unclear whether hs-CRP should be a treatment target, it is of interest to determine what types of therapeutic interventions produce changes in hs-CRP levels. Several recent studies indicate that statin treatment in patients with CAD produces significant reductions in hs-CRP—reductions that appear to be greater with regimens producing greater low-density lipoprotein cholesterol reductions.12, 13, 14
In a study of 509 patients with diabetes and triglyceride levels ≤6 mmol/L
Conceptual Framework for the Metabolic Syndrome
The management approach in patients with the metabolic syndrome depends on the syndrome’s perceived causes and the degree of risk attributed to its presence. Current general conceptual frameworks include (1) viewing the metabolic syndrome epidemic as being attributable to environmental causes (eg, the basic approach of NCEP ATP III), (2) viewing the syndrome as primarily the result of insulin resistance (eg, the WHO approach), and (3) viewing inflammation as the underlying cause of the
Conclusion
Ongoing investigation is required to determine how best to define the metabolic syndrome. Although it is clear that the presence of the syndrome is associated with increased cardiovascular risk, the levels of associated risk have not been clearly defined. Different proposed definitions would appear to result in different predictions of risk, and risk appears to differ according to which components of the proposed definitions are present. Inclusion of hs-CRP in the definition improves its
References (24)
- et al.
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitusa prospective study
Lancet
(2002) - et al.
Effect of rosuvastatin and atorvastatin on CRP levels in patients with type 2 diabetesresults from the ANDROMEDA study
Atheroscler Suppl
(2005) - et al.
Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with the metabolic syndromeresults from the COMETS study
Atheroscler Suppl
(2005) - IDF consensus worldwide definition of the metabolic syndrome. Available at:...
Executive summary of the third report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
JAMA
(2001)Part 1diagnosis and classification of diabetes mellitus
Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications
(1999)- et al.
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
N Engl J Med
(2002) - et al.
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
Circulation
(2003) - et al.
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study
Diabetes Care
(2002) - et al.
Chronic subclinical inflammation as part of the insulin resistance syndromethe Insulin Resistance Atherosclerosis Study (IRAS)
Circulation
(2000)
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetesthe Insulin Resistance Atherosclerosis Study
Diabetes
Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjectsimplications for preventing coronary heart disease during the prediabetic state
Circulation
Cited by (493)
The potential role of CpG oligodeoxynucleotides on diabetic cardiac autonomic neuropathy mediated by P2Y12 receptor in rat stellate ganglia
2023, International ImmunopharmacologyA healthy balance: the ratio of social support-to-demands is associated with metabolic syndrome
2024, Journal of Behavioral MedicineFactors Associated With the Cardiovascular Health of Black and Latino Adults With Type 2 Diabetes
2024, Biological Research for Nursing